Azithromycin May Reduce Hospitalization Frequency in COPD Patients

Aimee Simone, Pharmacy Times
Published Online: Friday, May 31, 2013
Follow Pharmacy_Times:
COPD patients who took azithromycin daily for a year were re-hospitalized at significantly lower rates than those who took placebo.

Long-term azithromycin therapy appears to lengthen the time between hospital visits for patients with chronic obstructive pulmonary disease (COPD), according to a study presented at the American Thoracic Society 2013 International Meeting, which took place May 17-22 in Philadelphia.
 
Researchers used data collected from a previous study of azithromycin use conducted by the COPD Clinical Research Network. Patients included in the study had COPD and had experienced an acute exacerbation of COPD in the 12 months before the start of the trial or were using supplemental oxygen when they enrolled in the study. Participants were randomly selected to receive a daily 250 mg dose of azithromycin or placebo for 1 year.
 
Throughout the year, the researchers kept track of re-hospitalizations for all participants, noting the reason for the hospitalization and measuring the amount of time that passed between hospital visits for respiratory causes. They then compared the time between hospital visits for patients taking azithromycin and for those in the placebo group.
 
After performing post-hoc analyses and adjusting for age, gender, and other general health factors, the researchers found that the gap between the first respiratory-related hospitalization and the second was longer for patients receiving the antibiotic than for those receiving placebo. Forty days into the trial, approximately 10% of patients in both groups had been re-hospitalized. However, after 200 days, just 20% of patients treated with azithromycin had been re-hospitalized for a respiratory-related event compared with approximately 40% of patients receiving the placebo.
 
Patients taking the antibiotic experienced 156 respiratory-related hospitalizations compared with 200 hospitalizations for patients in the placebo group. The study also found that 31 patients receiving azithromycin and 49 patients taking placebo were re-hospitalized for respiratory reasons. Azithromycin patients also suffered fewer hospital visits overall; 45 were re-hospitalized for any reason compared with 65 re-hospitalized placebo patients. The researchers note that patients in both groups who were re-hospitalized were of similar age and gender and adhered to similar inhaled medication regimens.
 
Although their results suggest that azithromycin therapy may improve the health of COPD patients, the researchers concluded that additional studies need to be carried out to validate their findings and to determine whether the antibiotic is a viable therapy option for COPD patients. In addition, the researchers noted that the benefit of long-term antibiotic therapy needs to be balanced against the risk of increased antibiotic resistance.

Related Articles
Bayer is expanding its aid donations for Ebola patients in Liberia and Sierra Leone.
Children exposed to antibiotics during the second or third trimester of pregnancy have an 84% higher risk of being obese at age 7 compared with children who were not exposed to the drugs in utero, according to new research published in the Journal of Obesity.
Antibiotic overuse and misuse threatens the efficacy of one of medicine’s most valuable lifesaving tools. Concurrently, research and development for new antibiotics has been limited – creating a problem for generations to come. The Society for Healthcare Epidemiology of America (SHEA) is joining the Centers for Disease Control and Prevention (CDC) and other partners in “Get Smart about Antibiotics Week” to highlight this alarming issue and raise awareness of strategies and programs to stop and reverse these trends.
With a mission to help pharmacists throughout the world prevent the potential spread of the Ebola virus, the International Pharmaceutical Federation has launched a suite of resources to advise community pharmacists on the threat.
Latest Issues
$auto_registration$